Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BioStock via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2026-05-29 10:19:00
The first few months of 2026 set a productive tone for Curasight. Following early positive data from the phase I trial in aggressive brain cancer, the company has fortified its board of directors by adding important industry players and also strengthened its financial base. BioStock contacted CEO Ulrich Krasilnikoff for a comment.
Read the full interview at biostock.se:
Curasight advances uTREAT through first-in-human development as key clinical data approaches
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/